Medication info

Dae Han Magnesium Sulfate Injection 50%

Prescription medicationInjectionsIntramuscular injection · Intravenous injection
Ingredient · strength
Magnesium Sulfate Hydrate›0.5g / 1mL
Manufacturer / importer
DaeHan Pharmaceutical Co., Ltd.
Appearance
A colorless and transparent liquid contained in a colorless and transparent glass ampule or a plastic aqueous injection container.
Packaging
50 ampules/box [(20mL/ampule)]
Approval status
Active

MFDS item code 200100340 · Notified 2001.05.07 · Insurance code 645101101

Summary

Main use
Electrolyte supplementation; suppression of hypomagnesemic convulsions and eclamptic seizures; prevention of uterine rigidity
Who receives it
Adults · Children
Adult administration
○ Convulsions due to hypomagnesemia: Administer 1 ∼ 2 g of magnesium sulfate intravenously (4.05 ∼ 8.1 mmol). ○ Seizures of eclampsia: Administer 4 ∼ 5 g of this drug intravenously over 10 minutes (16.2 ∼ 20.25 mmol). ○ Prevention of uterine rigidity: Administer an initial 4 g of this drug intravenously (16.2 mmol). A further 1 g may be administered. ○ Electrolyte replacement (hypomagnesemia): Administer 1 g of this drug intramuscularly every 6 hours for 4 doses. Alternatively, 5 g of this drug may be added to 5 % dextrose injection or 0.9 % normal saline injection and administered intravenously over 3 hours. During treatment of the deficiency, monitor the patient's renal excretory function closely.
Child administration
○ Children: The safety of this drug has not been studied.

Ingredients

Manufacturer
DaeHan Pharmaceutical Co., Ltd.

Efficacy & effects

Electrolyte supplementation; suppression of hypomagnesemic convulsions and eclamptic seizures; prevention of uterine rigidity

  • Cramps due to hypomagnesemia
  • eclampsia seizures
  • uterine contractions.
View approved original text

This medication is used to prevent and treat seizures caused by hypomagnesemia and eclampsia. It also helps prevent uterine contractions during childbirth and aids in correcting electrolyte imbalances such as hypomagnesemia. By effectively addressing various symptoms and conditions, it improves the health of patients.

How it is given

Adult administration

○ Convulsions due to hypomagnesemia: Administer 1 ∼ 2 g of magnesium sulfate intravenously (4.05 ∼ 8.1 mmol). ○ Seizures of eclampsia: Administer 4 ∼ 5 g of this drug intravenously over 10 minutes (16.2 ∼ 20.25 mmol). ○ Prevention of uterine rigidity: Administer an initial 4 g of this drug intravenously (16.2 mmol). A further 1 g may be administered. ○ Electrolyte replacement (hypomagnesemia): Administer 1 g of this drug intramuscularly every 6 hours for 4 doses. Alternatively, 5 g of this drug may be added to 5 % dextrose injection or 0.9 % normal saline injection and administered intravenously over 3 hours. During treatment of the deficiency, monitor the patient's renal excretory function closely.

Child administration

○ Children: The safety of this drug has not been studied.

Precautions

This medication is in the form of a glass ampule injection, so care must be taken when opening the ampule to avoid the risk of glass shards mixing in. Great care should be taken when administering it to children or the elderly. This medication should not be administered to patients with impaired kidney function, those with altered consciousness, patients with high magnesium levels in the blood, patients with cardiac conduction abnormalities, and patients with myasthenia gravis. Caution should be exercised when using this medication in children with intestinal parasitic infections or patients with heart disease. When using this medication, gastrointestinal symptoms such as vomiting or dry mouth may occur, and rarely symptoms like irregular heartbeats, vasodilation, headaches, tremors, and tingling may occur. Additionally, in cases of overdose, magnesium toxicity can lead to severe symptoms such as warmth, thirst, low blood pressure, central nervous system depression, decreased heart rate, and respiratory arrest, so caution is advised. In such cases, calcium preparations can be administered intravenously for detoxification. This medication may enhance central nervous system depression effects when used with barbiturates, narcotics, and other general anesthetics. Additionally, using it with iron supplements, specific antibiotics, sodium fluoride, etc., may reduce the absorption of these medications, so caution is necessary. It can also affect absorption with isoniazid, chlorpromazine, and digoxin, and when used with muscle relaxants, the muscle relaxant effect may increase. It can be used to treat eclampsia during pregnancy, but it may pass through the placenta and affect the fetus, causing decreased muscle tone, decreased reflexes, and low blood pressure. Administration during delivery may pose a risk of decreased newborn respiration, so the fetal heart rate should be closely monitored, and it should not be used within 2 hours after delivery. During prolonged or repeated use, the calcium and magnesium levels of the fetus and any skeletal anomalies should be monitored. Safety during lactation has not been established, and it is best not to administer it unless in special cases. Elderly patients may have reduced physical function, so the administration rate should be slowed down, and the dosage should be reduced, using caution. In cases of overdose, depending on the serum magnesium level, symptoms such as irregular heartbeats, decreased consciousness, respiratory depression, and cardiac arrest may occur, prompting immediate discontinuation of administration and, if necessary, incremental intravenous administration of calcium gluconate for detoxification. This medication should be diluted to below 10% concentration for slow intravenous administration, and mixing with certain medications may cause precipitation, so mixing should be avoided. Additionally, to prevent infection, the administration site and equipment must be thoroughly disinfected, and it should be used immediately after opening; any unused solution should not be reused.

Side effects

  • vomiting
  • dry mouth
  • conduction disorder
  • bradycardia
  • flushing
  • peripheral vasodilation
  • headache
  • feeling of heaviness
  • tremors
  • tingling
Show 7 more
  • sensation of heat
  • thirst
  • hypotension
  • central nervous system depression
  • heart rate inhibition
  • respiratory paralysis
  • warmth at the site of administration

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air and moisture ingress, ideally at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and prevent deterioration.

Appearance and packaging

Appearance

A colorless and transparent liquid contained in a colorless and transparent glass ampule or a plastic aqueous injection container.

Package unit

50 ampules/box [(20mL/ampule)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.